Peptides for Growth Hormone Research

Growth hormone research has seen the exploration of various peptides as potential secretagogues, with two notable candidates emerging in the literature: Tabimorelin and Alexamorelin. These compounds have been evaluated for their ability to stimulate growth hormone release, each presenting unique mechanisms and varying levels of evidence supporting their efficacy and safety. While Tabimorelin has undergone clinical trials, demonstrating its potential in stimulating growth hormone secretion, Alexamorelin remains largely in the preclinical stage with limited published data. This overview serves to contextualize the current state of research on these peptides and their implications for understanding growth hormone dynamics.

Tabimorelin (NN703) is a synthetic growth hormone secretagogue that has undergone Phase I and II clinical trials, primarily developed by Novo Nordisk. Research indicates that Tabimorelin effectively stimulates growth hormone release in both healthy individuals and those with growth hormone deficiency. In these trials, participants experienced significant increases in serum growth hormone levels, suggesting its potential utility in diagnosing growth hormone deficiency. However, despite these promising findings, the compound's development was halted, likely due to an unfavorable efficacy-to-side-effect ratio for chronic administration. Notably, Tabimorelin remains one of the more thoroughly characterized oral growth hormone secretagogues, contributing valuable insights into the pharmacological landscape of growth hormone regulation.

Alexamorelin is a synthetic growth hormone-releasing peptide (GHRP) that shares structural similarities with GHRP-6. Although it has been investigated as a potential growth hormone secretagogue, the extent of research is limited, with few preclinical studies published to date. These studies suggest that Alexamorelin may stimulate growth hormone release, but the lack of significant clinical development has left its efficacy and safety profile largely uncharacterized. As a result, Alexamorelin remains an obscure compound within the research community, with no regulatory approval or established clinical indication. The limited data available highlights the need for further investigation to elucidate its potential role in growth hormone research.